Cell & Gene Meeting on the Mesa 2022 Recap November 9, 2022 -- The Science and Medicine Group team was onsite at this year's Cell & Gene Meeting on the Mesa getting the who, what, and when on the product announcements, science sessions, and deals taking place this year. Find out what we learned in our recap.Read More
Gene therapy targets overactive brain cells in mice, potential neurological treatment November 4, 2022 -- University College London researchers have developed a gene therapy for neurological and psychiatric diseases that reduces the excitability of overactive brain cells. Tested in mice, the scientists contend the treatment could potentially be used in human brain diseases caused by excessive activity of a small number of brain cells.Read More
Academic CDMOs, like commercial ones, play critical role in CGT sector October 27, 2022 -- The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility.Read More
Induced pluripotent stem cell technology offers potential treatment for hair loss October 25, 2022 -- Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells.Read More
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia October 24, 2022 -- Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA.Read More
Antion Biosciences takes allogeneic approach to therapies with microRNA technology October 21, 2022 -- Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs.Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers October 20, 2022 -- In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies.Read More